A 48-year-old Bangladeshi gentle man presented with progressively increasing periorbital puffiness and redness and photosensitivity over the face for two and half months, arthritis of hand joints for 15 days, tightening and swelling of skin of the forearms, hands and thighs and proximal limb weakness for 12 days without any fever, Raynaud's phenomenon and difficulty in swallowing. He did not have anorexia or night sweats. He lost 2 kg in weight over this period. He was not abusing alcohol nor on any medication.
His face looked puffy and erythematous. His skin over face, fore arms, hands and thighs was shiny, taught and indurated. There were few painful, palpable purpura in fingers, legs and toes ( Figure 1 ). He was not anaemic and there was no lymphadenopathy. His metacarpophalangeal and proximal interphalangeal joints of both hands were swollen and tender. Muscle power specially in proximal groups was reduced (upper limb 3/5, lower limb 3/5). Deep tendon reflexes and plantar responses were normal. Other examination findings were unremarkable. and aldolase (23 U/L, normal up to 7.6) were markedly raised. Antinuclear antibody (ANA) was positive but none of the extractable nuclear antibodies (ENA) was positive. Anti-neutrophil cytoplasmic antibodies (ANCAs) were also negative. Serum bilirubin, electrolytes, thyroid function, chest X-ray and abdominal ultrasound were normal. Electromyography (EMG) was suggestive of inflammatory muscle disease (myositis). Histopathology of left calf muscles confirmed the diagnosis of dermatomyositis (Figure 2 ). CT scan of chest and abdomen and upper GI endoscopy were normal as were tumour markers. Treatment was started with prednisolone 1 mg/kg/day and azathioprine was added later on. Subcutaneous methotrexate was initiated because of poor response to prednisolone and azathioprine. But his response to medication was not good, rather weakness involved his neck muscles and he was unable to hold his neck in upright position and developed swallowing difficulty. Intravenous methyl prednisolone was added at a dose of 1 gm/day for 3 days without any benefit. As a precautionary measure, for the possibility of respiratory muscle involvement and respiratory failure the patient was shifted to intensive care unit (ICU).
At ICU endotracheal intubation was done for protection of air way and IVIg was started at a dose of 0.4 gm/kg/day and continued for 3 days. His muscle power improved to 4/5, but swallowing difficulty persisted. Tracheostomy was done as he was supposed to require long term endotracheal intubation for airway protection.
Two weeks later he was shifted to general ward with tracheostomy tube and nasogastric (NG) feeding tube in situ. After another one week, his biochemical and inflammatory parameters showed significant improvement (CPK 329 U/L, AST 94 U/l, ESR 54 mm in 1 st hour). His discharge medications included methotrexate 10 mg subcutaneously weekly and prednisolone 0.75 mg/kg/day along with folic acid, calcium and alendronate. Subsequent follow up visits at 2 nd , 5 th and 8 th weeks showed marked clinical and biochemical improvements. He can take food orally, NG tube was removed and closure of tracheostomy wound was done at 6 th week post-discharge.
Discussion
Diagnosis of dermatomyositis is straight-forward. In a patient with typical clinical presentation, demonstration of elevated muscle enzymes, EMG and muscle biopsy findings are sufficient to make a diagnosis. Drug response is often unsatisfactory in patients with dermatomyositis having dysphagia. Such patients need prolonged NG feeding or percutaneous gastrostomy and aggressive immunosuppressive therapy. [6] [7] [8] Respiratory paralysis and failure in dermatomyositis require endotracheal intubation and mechanical ventilation. 5 In few patients, non-invasive ventilations are of benefit. 4 On rare occasions, tracheostomy appears live saving. 9 One-third of adult onset dermatomyositis is associated with an occult malignancy, especially colorectal, bladder, lung, non-Hodgkin's lymphoma, ovarian, pancreatic and stomach cancers. If not found, their risk for developing cancer remains for up to five years. Some adult patients may have associated arthritis, Raynaud's etc. In such patients an overlap syndrome or mixed connective tissue disease should be excluded. 10 Corticosteroids are the mainstay of treatment. Resistant dermatomyositis is the term used to describe when disease does not respond to conventional immunosuppressive treatment. Such cases often need combination of immunosuppressive drugs, IVIg, anti-TNF or other agents. [11] [12] [13] [14] Response is variable but most reports are in favour of IVIg. Our patient initially did not respond to prednisolone, azathioprine, IV pulse methyl prednisolone but rapidly responded to IVIg. Now he is on subcutaneous methotrexate and tapering doses of prednisolone.
